Sanofi and GSK Phase 1/2 clinical trial of COVID-19 vaccine candidate
Sanofi and GSK have started the Phase 1/2 clinical trial for their adjuvanted COVID-19 vaccine.
The vaccine candidate, developed in partnership by Sanofi and GSK, uses the same recombinant protein-based technology as one of Sanofi’s seasonal influenza vaccines with GSK’s established pandemic adjuvant technology.
The Phase 1/2 clinical trial is a randomised, double blind and placebo-controlled trial designed to evaluate the safety, reactogenicity (tolerability) and immunogenicity (immune response) of the COVID-19 vaccine candidate. A total of 440 healthy adults are being enrolled in the trial across 11 investigational sites in the United States.
Sanofi is leading the clinical development and registration of the COVID-19 vaccine. Pre-clinical data showed an acceptable reactogenicity profile and data based on two injections of the adjuvanted recombinant vaccine showed high levels of neutralising antibodies that are comparable to levels in humans who recovered from the COVID-19 infection. Pre-clinical results will be published later this year. In parallel, Sanofi and GSK are scaling up manufacturing of the antigen and adjuvant with the target of producing up to one billion doses in 2021.
Thomas Triomphe, Executive Vice President and Global Head of Sanofi Pasteur, said: “Sanofi and GSK bring proven science and technology to the fight against the global COVID-19 pandemic, with the shared objective of delivering a safe and effective vaccine. The initiation of our clinical study is an important step and brings us closer to a potential vaccine which could help defeat COVID-19. Our dedicated teams and partner continue to work around the clock as we aim to deliver the first results in early December. Positive data will enable a prompt start of the pivotal phase 3 trial by the end of this year.”
Roger Connor, President of GSK Vaccines said: “Moving this vaccine candidate into clinical development is an important moment in the progress towards addressing the global pandemic we are all facing. This builds on the confidence shown by governments already in the potential of this protein-based adjuvanted vaccine candidate, which utilises established technology from both companies, and can be produced at scale by two of the leading vaccine manufacturers globally. We now look forward to the data from the study, and if positive, beginning a Phase 3 trial by the end of the year.”
Oxford University and AstraZeneca partner for COVID-19 vaccine candidate READ MORE
Novasep teams up with AstraZeneca to produce COVID-19 vaccine for Europe READ MORE
Dexamethasone identified as potential for treatment of COVID-19 ten weeks ago READ MORE
Symbiosis to manufacture COVID-19 vaccine for clinical trials READ MORE
Avacta positive on evaluation of COVID-19 test strips READ MORE
PrecisionLife identifies 68 genes associated with risk of severe COVID-19 READ MORE
Imaging system produces human cellular morphological data for COVID-19 research READ MORE
MMR vaccination might protect children from COVID-19 READ MORE
GSK receives first regulatory approval for Duvroq (daprodustat) in Japan READ MORE
EUSA Pharma receives FDA approval of phase III clinical trial for siltuximab READ MORE